Molecular probing of TNF

From identification of therapeutic target to guidance of therapy in inflammatory diseases

Cong-Qiu Chu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Therapy by blocking tumor necrosis factor (TNF) activity is highly efficacious and profoundly changed the paradigm of several inflammatory diseases. However, a significant proportion of patients with inflammatory diseases do not respond to TNF inhibitors (TNFi). Prediction of therapeutic response is required for TNFi therapy. Isotope labeled anti-TNF antibodies or TNF receptor have been investigated to localize TNF production at inflammatory tissue in animal models and in patients with inflammatory diseases. The . in vivo detection of TNF has been associated with treatment response. Recently, fluorophore labeled anti-TNF antibody in combination with confocal laser endomicroscopy in patients with Crohn's disease yielded more accurate and quantitative . in vivo detection of TNF in the diseased mucosa. More importantly, this method demonstrated high therapeutic predication value. Fluorophore labeled TNF binding aptamers in combination with modern imaging technology offers additional tools for . in vivo TNF probing.

Original languageEnglish (US)
JournalCytokine
DOIs
StateAccepted/In press - Jun 23 2016

Fingerprint

Tumor Necrosis Factor-alpha
Therapeutics
Fluorophores
Antibodies
Tumor Necrosis Factor Receptors
Isotopes
Crohn Disease
Mucous Membrane
Animals
Lasers
Animal Models
Tissue
Technology
Imaging techniques

Keywords

  • In vivo probing
  • Therapy
  • TNF

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Hematology
  • Molecular Biology

Cite this

Molecular probing of TNF : From identification of therapeutic target to guidance of therapy in inflammatory diseases. / Chu, Cong-Qiu.

In: Cytokine, 23.06.2016.

Research output: Contribution to journalArticle

@article{b03606abccd5418d882d0ec411793845,
title = "Molecular probing of TNF: From identification of therapeutic target to guidance of therapy in inflammatory diseases",
abstract = "Therapy by blocking tumor necrosis factor (TNF) activity is highly efficacious and profoundly changed the paradigm of several inflammatory diseases. However, a significant proportion of patients with inflammatory diseases do not respond to TNF inhibitors (TNFi). Prediction of therapeutic response is required for TNFi therapy. Isotope labeled anti-TNF antibodies or TNF receptor have been investigated to localize TNF production at inflammatory tissue in animal models and in patients with inflammatory diseases. The . in vivo detection of TNF has been associated with treatment response. Recently, fluorophore labeled anti-TNF antibody in combination with confocal laser endomicroscopy in patients with Crohn's disease yielded more accurate and quantitative . in vivo detection of TNF in the diseased mucosa. More importantly, this method demonstrated high therapeutic predication value. Fluorophore labeled TNF binding aptamers in combination with modern imaging technology offers additional tools for . in vivo TNF probing.",
keywords = "In vivo probing, Therapy, TNF",
author = "Cong-Qiu Chu",
year = "2016",
month = "6",
day = "23",
doi = "10.1016/j.cyto.2016.08.020",
language = "English (US)",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Molecular probing of TNF

T2 - From identification of therapeutic target to guidance of therapy in inflammatory diseases

AU - Chu, Cong-Qiu

PY - 2016/6/23

Y1 - 2016/6/23

N2 - Therapy by blocking tumor necrosis factor (TNF) activity is highly efficacious and profoundly changed the paradigm of several inflammatory diseases. However, a significant proportion of patients with inflammatory diseases do not respond to TNF inhibitors (TNFi). Prediction of therapeutic response is required for TNFi therapy. Isotope labeled anti-TNF antibodies or TNF receptor have been investigated to localize TNF production at inflammatory tissue in animal models and in patients with inflammatory diseases. The . in vivo detection of TNF has been associated with treatment response. Recently, fluorophore labeled anti-TNF antibody in combination with confocal laser endomicroscopy in patients with Crohn's disease yielded more accurate and quantitative . in vivo detection of TNF in the diseased mucosa. More importantly, this method demonstrated high therapeutic predication value. Fluorophore labeled TNF binding aptamers in combination with modern imaging technology offers additional tools for . in vivo TNF probing.

AB - Therapy by blocking tumor necrosis factor (TNF) activity is highly efficacious and profoundly changed the paradigm of several inflammatory diseases. However, a significant proportion of patients with inflammatory diseases do not respond to TNF inhibitors (TNFi). Prediction of therapeutic response is required for TNFi therapy. Isotope labeled anti-TNF antibodies or TNF receptor have been investigated to localize TNF production at inflammatory tissue in animal models and in patients with inflammatory diseases. The . in vivo detection of TNF has been associated with treatment response. Recently, fluorophore labeled anti-TNF antibody in combination with confocal laser endomicroscopy in patients with Crohn's disease yielded more accurate and quantitative . in vivo detection of TNF in the diseased mucosa. More importantly, this method demonstrated high therapeutic predication value. Fluorophore labeled TNF binding aptamers in combination with modern imaging technology offers additional tools for . in vivo TNF probing.

KW - In vivo probing

KW - Therapy

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=85009160056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009160056&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2016.08.020

DO - 10.1016/j.cyto.2016.08.020

M3 - Article

JO - Cytokine

JF - Cytokine

SN - 1043-4666

ER -